Trump Signs Hemp THC Ban Delay

WASHINGTON – President Donald Trump signed H.R. 6500, the Continuing Appropriations and Extensions Act, 2027, pushing back sweeping federal restrictions on hemp-derived THC products from November 12 to December 11, 2026. Embedded in a must-pass government funding bill, the extension keeps full-spectrum CBD, low-dose THC beverages, gummies, and other popular hemp formulations on store shelves for an additional 29 days while lawmakers work toward a regulatory alternative to outright prohibition.

The bill originated as a bipartisan effort to give Congress breathing room after it became clear that standalone hemp legislation, including the Lawful Hemp Protection Act introduced by Reps. Andy Barr (R) and Angie Craig (D) in July, was stalled in committee with no realistic path to a floor vote before November. The Senate cleared the package 90-6 on August 8, and the House followed on September 1.

Getting there was not without friction. Sen. Ted Budd (R), backed by fellow Republican senators, sought to preserve the original November 12 start date, arguing that intoxicating hemp products present documented risks, particularly to children. The Senate voted 61-32 to table that amendment, preserving the extension. Budd has pledged to continue his push against intoxicating hemp products when Congress reconvenes.

The backstory runs deeper than a single vote. The restrictions now being delayed were themselves passed the same way. Tucked into a government funding deal. Section 781 of Public Law 119-37, which Trump signed on November 12, 2025, rewrote the federal hemp definition created by the 2018 Farm Bill, capping total THC at 0.4 milligrams per container. That threshold would have effectively removed a large share of today’s consumer hemp market from federal legal protection. The 2018 Farm Bill, also signed by Trump during his first term, had legalized hemp containing less than 0.3 percent delta-9 THC on a dry-weight basis.

The current extension does not cover everything. The provision contains a carve-out that allows the immediate recriminalization, still on November 12, of synthetic cannabinoids that are not capable of being naturally [!] produced by a Cannabis plant, creating a two-tier structure that industry attorneys describe as technically difficult to parse. Delta-8 THC, which can occur naturally in Cannabis but is commercially produced through conversion, falls under the December reprieve, though what happens after December 11 remains far less certain.

White House positioning adds another layer of pressure. White House liaison James Braid signaled to Senate Republicans in August that the administration would not support another delay beyond December 11. Trump has, however, expressed support for regulation over prohibition. A December 2025 executive order directed federal officials to explore a framework that could include THC limits per serving, per-container limits, and CBD-to-THC ratio requirements, aiming to preserve access to what the administration called “appropriate full-spectrum CBD products.”

With the Farm Bill stalled over a separate and unrelated dispute about how quickly states should begin bearing additional SNAP costs, hemp’s legislative future now rests on Congress proving it can do something it has not yet managed – legislate hemp policy on its own terms, through a standalone bill, rather than through the next spending deadline.

December 11 is not a compromise. It is a deadline.

What the industry actually needs before December 11 is something no continuing resolution can provide – a durable federal standard with defined rules on potency thresholds, age-restricted access, and clear product categories. The reprieve signed this week is real. So is the reckoning that follows it.

Photo credit: Reuters/Carlos Barria